

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **TETRA BIO-PHARMA INC.** (the "Issuer" or "TETRA").

Trading Symbol: **TBP**

Number of Outstanding Listed Securities: **76,299,087**

Date: **November 4, 2016**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
 - 1) ***October 5, 2016, the Company entered into a non-binding agreement for a drawdown equity facility of up to \$2,000,0000. Each Offering will occur exclusively at the option of the Company, throughout the 18-month term of the agreement.***
The agreement provides for equity private placement offerings, to be conducted between Tetra and Alumina Partners LLC ("Alumina Partners"), a New York-based private equity firm.
 - 2) ***On October 19, that the National Sciences and Engineering Research Council***

of Canada (NSERC) has awarded an NSERC Engage Grant partnership to Tetra Bio-Pharma's subsidiary GrowPros MMP Inc. and Dr. Stan Kubow of McGill University.

3) On October 26, 2016 Tetra acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa (See point 9).

2. Provide a general overview and discussion of the activities of management.

The Company continues to focus on opportunities in the botanical based pharmaceuticals, while it continues to advance its application with Health Canada under the MMPR.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

- 6. October 5, 2016, the Company entered into a non-binding agreement for a drawdown equity facility of up to \$2,000,000. Each Offering will occur exclusively at the option of the Company, throughout the 18-month term of the agreement.***

The agreement provides for equity private placement offerings, to be conducted between Tetra and Alumina Partners LLC ("Alumina Partners"), a New York-based private equity firm.

On October 19, that the National Sciences and Engineering Research Council of Canada (NSERC) has awarded an NSERC Engage Grant partnership to Tetra Bio-Pharma's subsidiary GrowPros MMP Inc. and Dr. Stan Kubow of McGill University..

7. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

8. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

9. Describe the acquisition of new customers or loss of customers.

Not Applicable

10. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

On October 26, 2016 Tetra acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa. The assets acquired include proprietary formulations that have obtained marketing approval from Health Canada. The line consists of:

- 1. Glucose Aid; NPN 80058089***
- 2. Kava Kava; NPN 80061986***
- 3. Stress Aido; NPN 80065911***
- 4. Toux Aido (Cough Aido); NPN 80065923***
- 5. Toux enfant (Cough Children); NPN 80065928***
- 6. Water Relax; NPN 80065948 (beverage supplement)***
- 7. Water Cough; NPN 80066086 (beverage supplement)***
- 8. Sleep Pro; NPN 80066679***
- 9. Instant Relief; NPN 80066682 (topical gel for local pain relief).***

The acquisition of these formulations and their proprietary ingredients will provide PhytoPain Pharma Inc. with an inventory of compounds and elements that will be used as secondary ingredients or catalysts in the formulation of our pharmaceutical grade products.

11. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

12. Report on any labour disputes and resolutions of those disputes if applicable.

None

13. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

14. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

15. Provide details of any securities issued and options or warrants granted.

On October 26, 2016, the Company In consideration for the acquisition of the

assets, the Company has issued 1,800,000 common shares to arms' length individuals for the acquisition multiple intellectual property assets.

During the month of October 2,856,000 warrants were exercised.

16. Provide details of any loans to or by Related Persons.

None

17. Provide details of any changes in directors, officers or committee members.

None

18. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

1) Changes to the MMPPR or clinical trials requirements by Health Canada.

2) Changes in usage of natural health care products in Canada.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 4, 2016.

Sabino Di Paola
Name of Director or Senior Officer

signed "Sabino Di Paola"
Signature

Chief Financial Officer
Official Capacity

Issuer Details		
Name of Issuer	For Month End	Date of Report
Grow Pros Cannabis Ventures Inc.	2016/10/31	2016/11/04
Issuer Address		
99-5460 Canotek Road		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Ottawa, Ontario, K1J 9G9	(613) 421-8406	(613) 421-8402
Contact Name	Contact Position	Contact Telephone No.
Sabino Di Paola	CFO	(613) 241-2332
Contact Email Address	Web Site Address	
sabino@accmadeeasy.ca	www.growpros.ca	